RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer

Autor Porta, Camillo
Vydáno v Oncol Rev (2014)

RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane

Autor Porta, Camillo
Vydáno v Oncol Rev (2020)

Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system

Autor Porta, Camillo
Vydáno v ESMO Open (2020)

Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib

Autor Porta, Camillo, Paglino, Chiara
Vydáno 2010

ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics

Autor Porta, Camillo, Chiellino, Silvia
Vydáno v Ann Transl Med (2016)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Autor Rizzo, Mimma, Porta, Camillo
Vydáno v Ther Adv Urol (2017)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma

Autor Porta, Camillo, Paglino, Chiara, Mutti, Luciano
Vydáno 2008

Targeting PI3K/Akt/mTOR Signaling in Cancer

Autor Porta, Camillo, Paglino, Chiara, Mosca, Alessandra
Vydáno 2014

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial

Autor Porta, Camillo, Ganini, Carlo, Paglino, Chiara
Vydáno v Transl Androl Urol (2012)

Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents

Autor Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Bonomi, Lucia
Vydáno v ScientificWorldJournal (2007)

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or no...

Autor Porta, Camillo, Cosmai, Laura, Rizzo, Mimma, Melazzini, Mario
Vydáno v Ann Transl Med (2019)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

Autor Guarini, Chiara, Grassi, Teresa, Pezzicoli, Gaetano, Porta, Camillo
Vydáno v Int J Mol Sci (2021)

Renin angiotensin system deregulation as renal cancer risk factor

Autor Sobczuk, Paweł, Szczylik, Cezary, Porta, Camillo, Czarnecka, Anna M.
Vydáno v Oncol Lett (2017)

Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research

Autor Negri, Francesca, Missale, Gabriele, Antoni, Anna Degli, Porta, Camillo
Vydáno v Transl Oncol (2021)

Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?

Autor Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Ganini, Carlo, Pedrazzoli, Paolo
Vydáno 2011

Insulin-like growth factor-1 signaling in renal cell carcinoma

Autor Tracz, Adam F., Szczylik, Cezary, Porta, Camillo, Czarnecka, Anna M.
Vydáno v BMC Cancer (2016)

Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient

Autor Porta, Camillo, Ferrari, Alessandra, Czarnecka, Anna M., Szczylik, Cezary A.
Vydáno v Front Pharmacol (2017)

Choosing the right cell line for renal cell cancer research

Autor Brodaczewska, Klaudia K., Szczylik, Cezary, Fiedorowicz, Michal, Porta, Camillo, Czarnecka, Anna M.
Vydáno v Mol Cancer (2016)

Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer

Autor Internò, Valeria, Tucci, Marco, Pezzicoli, Gaetano, Silvestris, Franco, Porta, Camillo, Mannavola, Francesco
Vydáno v Front Oncol (2020)

Large Extracellular Vesicles—A New Frontier of Liquid Biopsy in Oncology

Autor Pezzicoli, Gaetano, Tucci, Marco, Lovero, Domenica, Silvestris, Franco, Porta, Camillo, Mannavola, Francesco
Vydáno v Int J Mol Sci (2020)